By Kim Richters
Germany's Bayer AG (BAYN.XE) said Wednesday that it has led a financing round in a U.S. startup researching potential cancer treatments.
The German conglomerate, which is battling legal cases in the U.S. tying its Roundup weedkiller to cancer, said it had invested $11 million in startup Pyxis Oncology via its investment arm Leaps by Bayer. Investors Agent Capital, Ipsen and Longwood Fund also contributed another $11 million, according to Bayer.
The newly founded Pyxis aims to develop antibody-based immunotherapies for cancer patients.
Write to Kim Richters at firstname.lastname@example.org